Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

If Donald Trump wins the presidency again in two weeks, this might be the ad that did it. It’s a spot called “Nonsense,” and it opens with a line so over the top, it feels like a parody ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

We want to take a moment to tell you about a graphic political ad you may have seen airing on ABC stations. The ad is for anti-abortion rights advocate and presidential candidate Randall Terry and ...

One reason behind the drugmaker's poor performance is that investors are worried about potential competition for Keytruda, Merck's famous cancer drug, which is by far its biggest growth driver.

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

V940 is an investigational individualized neoantigen therapy under development in combination with Keytruda (pembrolizumab) as adjuvant treatment for resectable Stage II, IIIA or IIIB (N2 ...

In the first two weeks of October, Donald Trump and his allies directed about a third of all their spending on broadcast TV advertisements to ads about transgender health care, a significant ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...